Market Overview

Is The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics?

Share:
Is The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics?

Analyzing the possibility of PTC Therapeutics, Inc. (NASDAQ: PTCT) receiving a complete response letter for its non-sense mutation Duchenne Muscular Dystrophy candidate Translarna, JPMorgan downgraded shares of the company.

Taking out U.S. Translarna from its model, which would eliminate $200 million to $250 million in peak revenue and about $7 per share, the firm downwardly revised its price target for the shares.

As such, the firm downgraded shares of PTC Therapeutics from Neutral to Underweight and lowered its price target from $23 to $15. The firm believes that the shares would be fairly valued in the mid-teens, as opposed to its current valuation.

At last check, PTC Therapeutics shares were sliding 5.86 percent to $18.48.

Analysts Anupam Rama, Eric Joseph and Yuko Oku noted that FDA's Advisory Panel voted definitely that the current Translarna data were inconclusive and more work is needed to determine its effectiveness. Therefore, the analysts see low probability of Translarna approval in the U.S.

The PDUFA date for Translarna is set for Oct. 24.

See also: Attention Biotech Investors, Here's Your PDUFA Primer For October

Moving onto another pipeline candidate, JPMorgan said it feels it is too early to tell the clinical potential for RG7916 on the World Muscle Society. The firm views the data for the treatment candidate in part 1 of the phase 2 SUNFISH study in Spinal Muscular Atrophy to be inconclusive. Therefore, the firm feels it does not warrant an increase in the probability of success.

"Currently, while OUS Translarna and US Emflaza sales do provide a valuation backstop, we do not see any material upside in PTCT shares nearterm; rather, we see potential meaningful downside risk, particularly given the high probability of complete response letter (CRL) later this month (while widely expected, sentiment / headline downside remains a risk and there is a valuation disconnect, in our view)," the firm said.

However, JPMorgan said it would look to get more constructive on PTC Therapeutics shares in the low-teens level.

_______
Image Credit: [Public domain], via Wikimedia Commons

Latest Ratings for PTCT

DateFirmActionFromTo
Apr 2019Initiates Coverage OnOutperform
Nov 2018MaintainsOverweightOverweight
Nov 2018MaintainsOutperformOutperform

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Downgrades Price Target FDA Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (PTCT)

View Comments and Join the Discussion!

Bank Earnings Pair Trade: Morgan Stanley Vs. Goldman Sachs

3 Ways To Play China's Rate Decision